Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Zardaverine is a dual inhibitor of phosphodiesterase 3 (PDE3) and PDE4 (IC50s = 0.617 and 1.738 μM, respectively, for the rat cardiac ventricle enzymes).1 It is selective for PDE3 and PDE4 over PDE1B, PDE2, and PDE5 (IC50s = >138 μM for all). Zardaverine inhibits aggregation of human platelets induced by ADP (Item No. 21121), platelet-activating factor (PAF), collagen, arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607), or prostaglandin E1 (PGE1; Item No. 13010) and ADP (IC50s = 1.5-16.2 μM). It inhibits zymosan-induced superoxide anion release from human polymorphonuclear (PMN) cells (IC50 = 0.4 μM). Zardaverine (10 μmol/kg) decreases lung resistance and increases dynamic compliance in a rat model of acetylcholine-induced bronchospasm.2 It decreases the viability of HeLa, COLO 741, NCI H2122, and A2058 cells that endogenously express high levels of PDE3A (IC50s = 0.032, 0.027, 0.26, and 0.13 μM, respectively), but is inactive against a panel of eight cancer cell lines that express low levels of PDE3A (IC50s = >16 μM for all).3
WARNING This product is not for human or veterinary use.
1. Zardaverine as a selective inhibitor of phosphodiesterase isozymes. Biochem. Pharmacol. 42(1), 153-162 (1991).
2. Comparative investigation of the effects of zardaverine and theophylline on pulmonary function in rats. Exp. Lung Res. 20(3), 235-250 (1994).
3. Targeting tumor cells based on phosphodiesterase 3A expression. Exp. Cell Res. 361(2), 308-315 (2017).